End-of-day quote
Taipei Exchange
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
38.75
TWD
|
-2.52%
|
|
+4.17%
|
+43.52%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,416
|
1,177
|
2,579
|
4,809
|
3,378
|
2,435
|
Enterprise Value (EV)
1 |
887.3
|
859.7
|
1,910
|
4,267
|
3,035
|
1,788
|
P/E ratio
|
-6.76
x
|
-5.25
x
|
-12
x
|
-38.2
x
|
-15.8
x
|
-11.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
944
x
|
373
x
|
768
x
|
935
x
|
488
x
|
479
x
|
EV / Revenue
|
591
x
|
272
x
|
569
x
|
830
x
|
438
x
|
352
x
|
EV / EBITDA
|
-4.15
x
|
-5.3
x
|
-11.8
x
|
-33.1
x
|
-14.3
x
|
-8.33
x
|
EV / FCF
|
-376
x
|
-3.92
x
|
-21.6
x
|
-54.3
x
|
-28.2
x
|
-15.3
x
|
FCF Yield
|
-0.27%
|
-25.5%
|
-4.63%
|
-1.84%
|
-3.55%
|
-6.53%
|
Price to Book
|
2.4
x
|
2.61
x
|
3.27
x
|
7.2
x
|
7.07
x
|
3.86
x
|
Nbr of stocks (in thousands)
|
57,213
|
61,137
|
89,227
|
89,227
|
90,200
|
90,200
|
Reference price
2 |
24.75
|
19.25
|
28.90
|
53.90
|
37.45
|
27.00
|
Announcement Date
|
24/04/19
|
22/04/20
|
21/04/21
|
06/06/22
|
11/04/23
|
11/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.501
|
3.156
|
3.359
|
5.141
|
6.923
|
5.082
|
EBITDA
1 |
-214.1
|
-162.1
|
-161.8
|
-129
|
-212
|
-214.6
|
EBIT
1 |
-215.3
|
-163.2
|
-163
|
-130.2
|
-213.1
|
-214.7
|
Operating Margin
|
-14,342.17%
|
-5,172.56%
|
-4,853.29%
|
-2,532.23%
|
-3,077.89%
|
-4,224.62%
|
Earnings before Tax (EBT)
1 |
-210.6
|
-220.8
|
-162.3
|
-127.5
|
-211.6
|
-212.3
|
Net income
1 |
-209.5
|
-217.8
|
-159.4
|
-125.6
|
-211.6
|
-212.3
|
Net margin
|
-13,960.63%
|
-6,900.03%
|
-4,745.04%
|
-2,443.36%
|
-3,056.15%
|
-4,177.33%
|
EPS
2 |
-3.663
|
-3.664
|
-2.411
|
-1.410
|
-2.370
|
-2.311
|
Free Cash Flow
1 |
-2.358
|
-219.5
|
-88.51
|
-78.63
|
-107.8
|
-116.7
|
FCF margin
|
-157.06%
|
-6,953.54%
|
-2,635.07%
|
-1,529.53%
|
-1,557.33%
|
-2,296.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/04/19
|
22/04/20
|
21/04/21
|
06/06/22
|
11/04/23
|
11/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
529
|
317
|
669
|
542
|
343
|
648
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.36
|
-219
|
-88.5
|
-78.6
|
-108
|
-117
|
ROE (net income / shareholders' equity)
|
-30.3%
|
-42%
|
-25.9%
|
-17.3%
|
-36.6%
|
-33.9%
|
ROA (Net income/ Total Assets)
|
-17.3%
|
-16.6%
|
-15.4%
|
-10.5%
|
-21.5%
|
-19.6%
|
Assets
1 |
1,212
|
1,314
|
1,038
|
1,192
|
985.5
|
1,082
|
Book Value Per Share
2 |
10.30
|
7.380
|
8.840
|
7.490
|
5.300
|
7.000
|
Cash Flow per Share
2 |
2.680
|
0.8400
|
1.020
|
0.3800
|
0.3900
|
1.450
|
Capex
1 |
0.11
|
-
|
0.11
|
0.67
|
-
|
-
|
Capex / Sales
|
7.33%
|
-
|
3.22%
|
12.97%
|
-
|
-
|
Announcement Date
|
24/04/19
|
22/04/20
|
21/04/21
|
06/06/22
|
11/04/23
|
11/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +43.52% | 132M | | +29.03% | 49.18B | | -0.10% | 42.11B | | +47.19% | 40.37B | | -5.26% | 28.85B | | +11.48% | 26.09B | | -22.74% | 18.71B | | +9.06% | 13.26B | | +30.01% | 12.32B | | -1.51% | 11.99B |
Other Biotechnology & Medical Research
|